PRME Company Profile and Key Details

Prime Medicine, Inc. (NASDAQ:PRME) closed at $3.13 USD, losing -$0.22 (-6.57%) from the previous close of $3.35. The stock is currently mid-range between its 52-week high and low $2.67 and $6.94. With a market capitalization of about $565.33 million, Prime Medicine, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.35). Key stats such as the average daily volume over the past year has been around 3.29 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Prime Medicine, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Allan Reine, the company employs approximately 146 people and listed since October 20, 2022. Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.

Prime Medicine, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.44. This means the shares are trading below this model’s fair value.

Short-term trend indicators are mixed aligned (SMA20 21.98%, SMA50 16.26%, SMA200 17.84%). The stock’s 14-day RSI is 65.75 (firm momentum), while the ATR of 0.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.89% below its high and over 294.59% above its low. Average 10-day trading volume of 2.98 million shares is in line with the 3-month average of 3.28 million, indicating normal recent market interest.

Prime Medicine, Inc. has 180.62 million shares outstanding. The public float is 114.96 million shares, elevated short interest at 23.76% of float. This equals 33.54 million shares. The short ratio is 7.65 days. Institutional investors hold 87.49% of the float. Insiders own 23.76%. Liu David R. holds 20.24 million shares, ARCH Venture Partners X, LLC has 6.23 million shares and ARCH Venture Partners XII, LLC has 6.23 million shares.

Prime Medicine, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -124.13%. Wall Street analysts project EPS growth of 20.13% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.25. Next year's EPS is expected at $5.24. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $4.25. The high target offers 251.44% upside. The low target suggests 35.78% downside. The mean target is $7.65. This offers 144.41% upside. Prime Medicine, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -6.7%. The prior quarter beat by 16.67%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in May 08, 2025.

Prime Medicine, Inc. trades at a P/E ratio of -2.85, slightly below the S&P 500 average, with a price-to-sales ratio of 138.8 and a price-to-book ratio of 13.93 reflecting a rich premium to book value. The P/FCF stands at -3.6, also below market averages. Compared to sector medians, Prime Medicine, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Prime Medicine, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.18%, with price expected at $3.48 by September 25, 2026, within a range of $3.32 to $3.64 3-Month Outlook: Projected rise of 16.29%, reaching $3.64 by December 10, 2026, with a range of $3.13 to $3.99. 1-Year Outlook: Projected gain of 97.44%, with price at $6.18 by September 10, 2027, within a range of $0.00 to $5.11.

Prime Medicine, Inc. (NASDAQ:PRME) shares are up 12.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Prime Medicine, Inc. trading at a premium to the broader market with a P/E of -2.85. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.01, suggesting 347.6% upside. Our AI forecast model points to short-term strength (11.18% over two weeks), a medium-term rise (16.29% over three months), and a longer-term gain (97.44% over one year), with expected trading ranges indicating moderate volatility.